| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P819 | ADS bibcode | 2013PLoSO...871251X |
| P356 | DOI | 10.1371/JOURNAL.PONE.0071251 |
| P932 | PMC publication ID | 3735494 |
| P698 | PubMed publication ID | 23940730 |
| P5875 | ResearchGate publication ID | 255791214 |
| P2093 | author name string | Li Huang | |
| Zhihai Peng | |||
| Lin Zhong | |||
| Zhenhai Yu | |||
| Shuyun Wang | |||
| Tonghai Xing | |||
| P2860 | cites work | Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation | Q46185590 |
| Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria | Q46187843 | ||
| Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation | Q46719513 | ||
| Initial immunosuppression with or without basiliximab: a comparative study. | Q54386145 | ||
| Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity | Q71568609 | ||
| Pros and cons of using interleukin-2 receptor antibodies in liver transplant recipients | Q77681742 | ||
| Liver transplantation for hepatocellular carcinoma: Hangzhou experiences | Q81525414 | ||
| Control of hepatitis B in China: prevention and treatment | Q82961485 | ||
| The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma | Q83828867 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection | Q28304336 | ||
| Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. | Q30863690 | ||
| Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience | Q33371289 | ||
| Early steroid withdrawal after liver transplantation for hepatocellular carcinoma | Q34225664 | ||
| Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial | Q34598408 | ||
| Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. | Q34684679 | ||
| Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China | Q34976928 | ||
| Hepatocellular carcinoma: focus on different aspects of management | Q35986436 | ||
| The role of basiliximab induction therapy in organ transplantation | Q36675465 | ||
| Hepatocellular carcinoma: A global view. | Q37589349 | ||
| Current status of liver diseases in Korea: hepatocellular carcinoma | Q37663515 | ||
| Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge | Q38045000 | ||
| Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma | Q38070693 | ||
| Glucocorticoid protects hepatoma cells against metabolic stress-induced cell death. | Q39914354 | ||
| Seroprevalence of hepatitis B surface antigen among pregnant women in Jiangsu, China, 17 years after introduction of hepatitis B vaccine | Q39919387 | ||
| Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. | Q39984667 | ||
| Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy | Q40341969 | ||
| Insulin and dexamethasone inhibit TGF-beta-induced apoptosis of hepatoma cells upstream of the caspase activation cascade | Q40511983 | ||
| Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial | Q40657873 | ||
| A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. | Q43039814 | ||
| Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma | Q43185126 | ||
| Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center | Q43254708 | ||
| Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study | Q43943540 | ||
| Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage | Q44910175 | ||
| Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study | Q45159362 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P5824 | is retracted by | Retraction: Comparison of Steroid-Free Immunosuppression and Standard Immunosuppression for Liver Transplant Patients with Hepatocellular Carcinoma | Q93099589 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| immunosuppression | Q1455316 | ||
| P304 | page(s) | e71251 | |
| P577 | publication date | 2013-08-06 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma | |
| Retracted: Comparison of Steroid-Free Immunosuppression and Standard Immunosuppression for Liver Transplant Patients with Hepatocellular Carcinoma | |||
| P478 | volume | 8 |
| Q38205739 | Current strategies for immunosuppression following liver transplantation |
| Q89379957 | Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? |
| Q92449431 | Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: A multicenter European experience |
| Q36962089 | Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome |
| Q38635611 | Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival |
| Q38177251 | Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis |
| Q89092238 | Meta-Analysis of the Effects of Exercise Training on Markers of Metabolic Syndrome in Solid Organ Transplant Recipients |
| Q89953483 | Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence |
| Q37376461 | Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study |
| Q28545113 | Retracted: Comprehensive Comparison of Three Different Immunosuppressive Regimens for Liver Transplant Patients with Hepatocellular Carcinoma: Steroid-Free Immunosuppression, Induction Immunosuppression and Standard Immunosuppression |
| Q93099589 | Retraction: Comparison of Steroid-Free Immunosuppression and Standard Immunosuppression for Liver Transplant Patients with Hepatocellular Carcinoma |
| Q96823562 | Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a trial |
| Q52567486 | Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation. |
| Q42431701 | Towards Steroid-Free Immunosuppression after Liver Transplantation |
| Q92677186 | Vitamin D supplementation could reduce the risk of acute cellular rejection and infection in vitamin D deficient liver allograft recipients |
Search more.